Aclaris Therapeutics (ACRS) Net Margin (2017 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly Net Margin of 1876.8% for Q1 2026, down 60608.0% year-over-year from N/an in Q1 2025, and up 22.39% quarter-over-quarter from 2418.38% in Q4 2025.
Aclaris Therapeutics (ACRS) Net Margin (2017 - 2026) Analysis & Trends
Aclaris Therapeutics' Net Margin history runs 10 years deep, the most recent figure standing at 1876.8% for Q1 2026.
- In Q1 2026, Net Margin fell 60608.0% year-over-year to 1876.8%; the TTM figure through Mar 2026 stood at 1276.87% (down 44491.0% YoY), while the FY2025 annual figure was 3488.03%, down 278255.0% from the prior year.
- Net Margin for Q1 2026 stood at 1876.8%, up from 2418.38% in the prior quarter.
- The five-year high for Net Margin was 191.34% in Q3 2022, with the low at 2615.97% in Q1 2022.
- The 5-year median for Net Margin is 1121.13% (2023), against an average of 1184.59%.
- The sharpest annual moves came in 2022 and 2025: Net Margin soared 212572 bps in 2022, then sank 124272 bps in 2025.
- Aclaris Therapeutics' Net Margin stood at 564.93% in 2022, then sank by 98 bps to 1121.13% in 2023, then dropped by 5 bps to 1175.66% in 2024, then slumped by 106 bps to 2418.38% in 2025, then advanced by 22 bps to 1876.8% in 2026.
- Business Quant data shows ACRS's Net Margin at 1876.8% in Q1 2026, 2418.38% in Q4 2025, and 581.72% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | -3,370.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,370.60% |
| Mar 31, 2026 | -1,876.80% |
| Dec 31, 2025 | -2,418.38% |
| Sep 30, 2025 | -581.72% |
| Jun 30, 2025 | -1,061.68% |
| Mar 31, 2025 | -1,270.72% |
| Dec 31, 2024 | -1,175.66% |
| Sep 30, 2024 | -222.32% |
| Jun 30, 2024 | -414.50% |
| Mar 31, 2024 | -726.77% |
| Dec 31, 2023 | -1,121.13% |
| Sep 30, 2023 | -354.89% |
| Jun 30, 2023 | -2,086.57% |
| Mar 31, 2023 | -1,349.60% |
| Dec 31, 2022 | -564.93% |
| Sep 30, 2022 | -191.34% |
| Jun 30, 2022 | -2,105.04% |
| Mar 31, 2022 | -2,615.97% |
| Dec 31, 2021 | -2,453.50% |
| Sep 30, 2021 | -2,317.06% |